A5022703852- Pain Management and Opioid Use
- Pain Mechanisms and Treatments
- Fibromyalgia and Chronic Fatigue Syndrome Research
- Palliative Care and End-of-Life Issues
- Genomics and Rare Diseases
- Cannabis and Cannabinoid Research
- Childhood Cancer Survivors' Quality of Life
- Cancer survivorship and care
- Pharmacological Effects and Toxicity Studies
- Mast cells and histamine
- Botulinum Toxin and Related Neurological Disorders
- Pancreatic and Hepatic Oncology Research
- Food Allergy and Anaphylaxis Research
- Inflammatory Myopathies and Dermatomyositis
- Neurogenetic and Muscular Disorders Research
- Child and Adolescent Psychosocial and Emotional Development
- Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Hereditary Neurological Disorders
- Nutrition and Health in Aging
- Psychiatric care and mental health services
- Pediatric Pain Management Techniques
- Urticaria and Related Conditions
- Musculoskeletal pain and rehabilitation
- Opioid Use Disorder Treatment
- Pain Management and Placebo Effect
RWTH Aachen University
2022-2024
University Hospital Bonn
2015-2024
Universitätsklinikum Aachen
2022-2024
University of Bonn
2016-2024
Medizinische Hochschule Hannover
2023
Centrum für Integrierte Onkologie
2017-2022
Helmholtz Centre for Infection Research
2022
Ostfalia University of Applied Sciences
2022
Luisenhospital Aachen
2022
University of Basel
2019
Background Worldwide approximately 7,000 rare diseases have been identified. Accordingly, 4 million individuals live with a disease in Germany. The mean time to diagnosis is about 6 years and patients receive several incorrect diagnoses during this time. A multiplicity of factors renders diagnosing extremely difficult. Detection shared phenomena among different could assist the diagnostic process. In order explore demand for support obtain commonalities patients, nationwide Delphi survey...
Abstract Individuals with ultrarare disorders pose a structural challenge for healthcare systems since expert clinical knowledge is required to establish diagnoses. In TRANSLATE NAMSE, 3-year prospective study, we evaluated novel diagnostic concept based on multidisciplinary expertise in Germany. Here present the systematic investigation of phenotypic and molecular genetic data 1,577 patients who had undergone exome sequencing were partially analyzed next-generation phenotyping approaches....
<b>Purpose:</b> Evaluation of ultrasound-guided high-intensity focused ultrasound (HIFU) used for the first time in Germany patients with inoperable pancreatic cancer reduction tumor volume and relief tumor-associated pain. <b>Materials Methods:</b> 15 locally advanced tumor-related pain symptoms were treated by HIFU (n = 6 UICC stage III, n 9 IV). 13 underwent simultaneous standard chemotherapy. Ablation was performed using JC system (Chongqing, China HAIFU Company) an ultrasonic device...
Pancreatic cancer (PaC) is a life-limiting tumor with wide range of incapacitating symptoms such as pain in more than 80 % patients. This prospective interventional study addresses the clinical effectiveness ultrasound-guided high-intensity focused ultrasound (HIFU) treatment for patients advanced-stage PaC, including perception, size and survival benefit. 50 late-stage PaC underwent HIFU. Clinical assessment included evaluation volume by imaging burden (pain severity, sensation,...
Abstract Most individuals with rare diseases initially consult their primary care physician. For a subset of diseases, efficient diagnostic pathways are available. However, ultra-rare often require both expert clinical knowledge and comprehensive genetic diagnostics, which poses structural challenges for public healthcare systems. To address these within Germany, novel structured concept, based on multidisciplinary expertise at established university hospital centers (CRDs), was evaluated in...